Skip to main content
Premium Trial:

Request an Annual Quote

Amprion SynTap Biomarker Test

Amprion, a San Francisco-based biomarker testing company, has launched the SynTap Biomarker test out of its San Diego CLIA lab. The laboratory-developed test is designed to detect a-synuclein aggregates, a hallmark in various brain diseases. As such, the assay aids in diagnosing synucleinopathies such as Parkinson's disease, Lewy body dementia, and multiple system atrophy. In addition, the test helps distinguish underlying synucleinopathies in other neurodegenerative conditions, such as Alzheimer's disease. Based on Amprion's proprietary Seed Aggregation Assay technology, SynTap identifies prion-like a-synuclein aggregates using approximately 100 µl of cerebrospinal fluid. Test results are intended to accompany other clinical and diagnostic findings for patient case management, the company said.